Diurnal Group (AIM: DNL)

Last close As at 12/07/2024

27.30

0.00 (0.00%)

Market capitalisation

GBP46m

Latest Insights

View More

Healthcare | Flash note

Diurnal Group — Proposed acquisition by Neurocrine Biosciences

Healthcare | Flash note

Diurnal Group — Alkindi sales underpin top-line growth

Healthcare | Flash note

Diurnal Group — First patient dosed in the US CONnECT study

Healthcare | Flash note

Diurnal Group — Leveraging the known pathway

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 1.7 163.1 (55.3)
Relative 8.4 174.9 (52.2)
52 week high/low 66.5p/9.8p

Financials

Edison Investment Research is terminating coverage on Vivesto (VIVE), Diurnal Group (DNL), Palace Capital (PCA), Primary Health Properties (PHP), Silver One Resources (SVE), Induction Healthcare (INHC) and Axiom European Financial Debt (AXI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.

Y/E Jun Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2020A 6.3 (5.2) (5.1) (4.1) N/A N/A
2021A 4.4 (11.1) (11.1) (7.0) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free